Cidara also is leveraging its novel Cloudbreak platform to develop antibody-drug conjugates for the treatment of serious viral and Gram-negative bacterial infections
The Potentiator Platform molecules are designed to treat Gram-negative bacterial infections
The company said Zavicefta (ceftazidime-avibactam) is a fixed-dose combination antibacterial that was developed to treat serious Gram-negative bacterial infections
. It consists of a combination of avibactam and ceftazidime - a third-generation antipseudomonal cephalosporin with a well-established efficacy and safety profile.
CAZ-AVI (ceftazidime-avibactam) is an investigational antibiotic being developed to treat serious Gram-negative bacterial infections
. It consists of ceftazidime, a third-generation, antipseudomonal cephalosporin, that is an established treatment for serious Gram-negative bacterial infections
, and avibactam, a next generation, non-beta lactam beta-lactamase inhibitor.
However, endotoxemia in liver transplant recipients has been associated with graft failure and a high mortality rate (4,5), and in gram-negative bacterial infections
, the physiologic effects of endotoxin may persist after adequate antimicrobial drug treatment.
Cidara also is leveraging its novel Cloudbreak platform to develop antibody-drug conjugates for the treatment of multi-drug resistant Gram-negative bacterial infections
The grant will fund the continued research and development of Cidara's Cloudbreak antibody-drug conjugate platform to identify novel immunotherapy agents for the treatment and prevention of serious and life-threatening multi-drug resistant gram-negative bacterial infections
in high-risk patient populations.
Pfizer's (NYSE:PFE) novel combination antibiotic for patients with serious Gram-negative bacterial infections
, Zavicefta, has been launched in the UK and Germany, the company announced on Tuesday.
meningosepticum infections are rare, accurate diagnosis is important because the species is usually resistant to multiple antibiotics, especially to those (including extended-spectrum [Beta]-lactam agents and aminoglycosides) typically prescribed for treatment of aerobic, gram-negative bacterial infections
. Moreover, epidemics may occur, and a death rate as high as 55% has been reported in a nursery outbreak (8,9).